Sargent Bickham Lagudis’s Juno Therapeutics, Inc. JUNO Stock Holding History

Sargent Bickham Lagudis’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-94	Closed	-$4K	–	833
2017 Q4	$4K	Hold	94	–	–	﹤0.01%	716
2017 Q3	$4K	Hold	94	–	–	﹤0.01%	721
2017 Q2	$3K	Hold	94	–	–	﹤0.01%	707
2017 Q1	$2K	Hold	94	–	–	﹤0.01%	710
2016 Q4	$2K	Hold	94	–	–	﹤0.01%	678
2016 Q3	$3	Hold	94	–	–	﹤0.01%	673
2016 Q2	$4K	Hold	94	–	–	﹤0.01%	635
2016 Q1	$4K	Buy	+94	New	+$3.27K	﹤0.01%	659

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Sargent Bickham Lagudis's JUNO Position: Q1 2018 in Review

Sargent Bickham Lagudis sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 94 shares — an estimated $4K sold.

Sargent Bickham Lagudis first reported a position in JUNO in Q1 2016 and held it in 8 quarters. The position peaked at $4K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Sargent Bickham Lagudis reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Sargent Bickham Lagudis sold 94 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $4K.
Sargent Bickham Lagudis first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
Sargent Bickham Lagudis's Juno Therapeutics, Inc. position peaked at $4K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2018, filed 13 Sep 2021.